RANGRF

Summary

RANGRF (RAN guanine nucleotide release factor, HGNC:17679) is a protein-coding gene on chromosome 17p13.1, encoding Ran guanine nucleotide release factor (Q9HD47). May regulate the intracellular trafficking of RAN.

This gene encodes a protein that has been shown to function as a guanine nucleotide release factor in mouse and to regulate the expression and function of the Nav1.5 cardiac sodium channel in human. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 29098 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Brugada syndrome (Limited, GenCC)
• Clinical variants (ClinVar): 153 total
• Phenotypes (HPO): 12
• MANE Select transcript: NM_016492

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17679
Approved symbol	RANGRF
Name	RAN guanine nucleotide release factor
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	MOG1, HSPC165, HSPC236, RANGNRF
Ensembl gene	ENSG00000108961
Ensembl biotype	protein_coding
OMIM	607954
Entrez	29098

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 retained_intron

ENST00000226105, ENST00000407006, ENST00000439238, ENST00000578849, ENST00000580434, ENST00000580777, ENST00000879547, ENST00000879548, ENST00000939480

RefSeq mRNA: 4 — MANE Select: NM_016492 NM_001177801, NM_001177802, NM_001330127, NM_016492

CCDS: CCDS11137, CCDS54086, CCDS54087, CCDS82066

Canonical transcript exons

ENST00000226105 — 5 exons

Exon	Start	End
ENSE00000855075	8289503	8289588
ENSE00001233099	8288956	8289072
ENSE00002701334	8288670	8288865
ENSE00003589475	8289813	8290087
ENSE00003634718	8289258	8289414

Expression profiles

Bgee: expression breadth ubiquitous, 274 present calls, max score 96.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.0747 / max 153.3689, expressed in 1785 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159479	18.4551	1785
159481	0.6196	348

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	96.67	gold quality
right testis	UBERON:0004534	96.27	gold quality
testis	UBERON:0000473	95.07	gold quality
granulocyte	CL:0000094	93.98	gold quality
apex of heart	UBERON:0002098	93.70	gold quality
nucleus accumbens	UBERON:0001882	93.09	gold quality
lower esophagus muscularis layer	UBERON:0035833	92.77	gold quality
lower esophagus	UBERON:0013473	92.72	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	92.65	gold quality
body of stomach	UBERON:0001161	92.51	gold quality
caudate nucleus	UBERON:0001873	92.35	gold quality
left uterine tube	UBERON:0001303	92.34	gold quality
body of uterus	UBERON:0009853	92.32	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.23	gold quality
putamen	UBERON:0001874	92.17	gold quality
heart left ventricle	UBERON:0002084	91.84	gold quality
right atrium auricular region	UBERON:0006631	91.81	gold quality
endocervix	UBERON:0000458	91.80	gold quality
cardiac ventricle	UBERON:0002082	91.56	gold quality
adult organism	UBERON:0007023	91.44	gold quality
left ovary	UBERON:0002119	91.41	gold quality
right ovary	UBERON:0002118	91.27	gold quality
thoracic aorta	UBERON:0001515	91.26	gold quality
ascending aorta	UBERON:0001496	91.25	gold quality
right coronary artery	UBERON:0001625	91.25	gold quality
left coronary artery	UBERON:0001626	91.06	gold quality
adenohypophysis	UBERON:0002196	91.02	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.89	gold quality
aorta	UBERON:0000947	90.80	gold quality
coronary artery	UBERON:0001621	90.64	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

9 targeting RANGRF, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-3679-3P	99.64	69.88	1599
HSA-MIR-142-5P	99.48	70.92	2416
HSA-MIR-5590-3P	99.48	70.91	2429
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-550A-3P	98.37	69.61	632
HSA-MIR-6787-3P	97.75	66.17	1233

Literature-anchored findings (GeneRIF, showing 6)

• in cardiomyocytes, MOG1 is mostly localized in the cell membrane and co-localized with Nav1.5, indicating that MOG1 is a critical regulator of sodium channel function in the heart (PMID:18184654)
• Results suggest that dominant-negative mutations in MOG1 can impair the trafficking of Na(v)1.5 to the membrane, leading to I(Na) reduction and clinical manifestation of Brugada syndrome. (PMID:21447824)
• Our screening of Nav1.5 cofactor MOG1 uncovered a novel nonsense variant that appeared to be present at a higher frequency among these patients with atrial fibrillation and Brugada syndrome than control subjects. (PMID:21621375)
• Suggest that p.E61X_RANGRF is a rare genetic variation with an uncertain role in Brugada Syndrome. (PMID:24142675)
• Compound mutation of CACNA2D1 and RANGRF genes were found. To the best of our knowledge, this is the first comprehensive description of the concurrence of these two mutations and histiocytoid cardiomyopathy. (PMID:24438356)
• The MOG1 domain required for the interaction with Nav1.5 to the region spanning amino acids 146-174, and a refined deletion analysis further narrowed this domain to amino acids146-155. (PMID:30282806)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	rangrf	ENSDARG00000098786
mus_musculus	Rangrf	ENSMUSG00000032892
rattus_norvegicus	Rangrf	ENSRNOG00000004980
rattus_norvegicus		ENSRNOG00000066806

Protein

Protein identifiers

Ran guanine nucleotide release factor — Q9HD47 (reviewed: Q9HD47)

Alternative names: Ran-binding protein MOG1

All UniProt accessions (1): Q9HD47

UniProt curated annotations — full annotation on UniProt →

Function. May regulate the intracellular trafficking of RAN. Promotes guanine nucleotide release from RAN and inhibits binding of new GTP by preventing the binding of the RAN guanine nucleotide exchange factor RCC1. Regulates the levels of GTP-bound RAN in the nucleus, and thereby plays a role in the regulation of RAN-dependent mitotic spindle dynamics. Enhances the expression of SCN5A at the cell membrane in cardiomyocytes.

Subunit / interactions. Monomer. Interacts with RAN, both RAN-GTP and RAN-GDP. Competes with RCC1 for a common binding site on RAN and thereby inhibits RCC1-mediated nucleotide exchange. Forms a complex with RAN-GTP and RANBP1. Interacts with the cytoplasmic loop 2 of SCN5A.

Subcellular location. Nucleus. Cytoplasm. Perinuclear region. Cell membrane.

Tissue specificity. Isoform 1 and isoform 2 are ubiquitously expressed. Detected in heart and brain.

Miscellaneous. Overexpression can rescue the trafficking defect caused by some SCN5A mutations that impair trafficking to the cell membrane.

Similarity. Belongs to the MOG1 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9HD47-1	1, MOG1a	yes
Q9HD47-2	2, MOG1b
Q9HD47-3	3
Q9HD47-4	4

RefSeq proteins (4): NP_001171272, NP_001171273, NP_001317056, NP_057576* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007681	Mog1	Family
IPR016123	Mog1/PsbP_a/b/a-sand	Homologous_superfamily

Pfam: PF04603

UniProt features (32 total): strand 9, helix 5, splice variant 5, mutagenesis site 4, turn 4, sequence variant 2, chain 1, region of interest 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5YFG	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HD47-F1	78.36	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (4):

Position	Phenotype
50	strongly decreased binding to ran. abolishes binding to ran; when associated with k-53.
53	decreased binding to ran. abolishes binding to ran; when associated with k-50.
70	decreased binding to ran.
27	decreased binding to ran.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-5576892	Phase 0 - rapid depolarisation
R-HSA-397014	Muscle contraction
R-HSA-5576891	Cardiac conduction

MSigDB gene sets: 231 (showing top): GOBP_CHROMOSOME_ORGANIZATION, GOBP_MEMBRANE_DEPOLARIZATION, GOBP_BUNDLE_OF_HIS_CELL_TO_PURKINJE_MYOCYTE_COMMUNICATION, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_SODIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_MEMBRANE_DEPOLARIZATION_DURING_ACTION_POTENTIAL, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, DITTMER_PTHLH_TARGETS_UP, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION_TO_CELL_SURFACE, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_MEMBRANE_DEPOLARIZATION, GOMF_GTPASE_BINDING, GOBP_POSITIVE_REGULATION_OF_MEMBRANE_DEPOLARIZATION, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY

GO Biological Process (14): regulation of heart rate (GO:0002027), regulation of membrane depolarization (GO:0003254), endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888), protein exit from endoplasmic reticulum (GO:0032527), heart contraction (GO:0060047), mitotic spindle assembly (GO:0090307), regulation of bundle of His cell action potential (GO:0098905), regulation of cardiac muscle cell action potential involved in regulation of contraction (GO:0098909), regulation of membrane depolarization during cardiac muscle cell action potential (GO:1900825), positive regulation of membrane depolarization during cardiac muscle cell action potential (GO:1900827), regulation of sodium ion transmembrane transport (GO:1902305), positive regulation of protein localization to plasma membrane (GO:1903078), positive regulation of protein localization to cell surface (GO:2000010), protein transport (GO:0015031)

GO Molecular Function (6): guanyl-nucleotide exchange factor activity (GO:0005085), sodium channel regulator activity (GO:0017080), small GTPase binding (GO:0031267), transmembrane transporter binding (GO:0044325), channel activator activity (GO:0099103), protein binding (GO:0005515)

GO Cellular Component (10): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), rough endoplasmic reticulum (GO:0005791), cytosol (GO:0005829), plasma membrane (GO:0005886), caveola (GO:0005901), intercalated disc (GO:0014704), perinuclear region of cytoplasm (GO:0048471), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Cardiac conduction	1
Muscle contraction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
cytoplasm	4
regulation of cardiac muscle cell action potential	2
membrane depolarization during cardiac muscle cell action potential	2
regulation of heart contraction	1
regulation of biological quality	1
regulation of membrane potential	1
regulation of cellular process	1
membrane depolarization	1
intercellular transport	1
intracellular transport	1
Golgi vesicle transport	1
intracellular protein transport	1
heart process	1
blood circulation	1
mitotic sister chromatid segregation	1
mitotic spindle organization	1
spindle assembly	1
mitotic nuclear division	1
bundle of His cell action potential	1
cardiac muscle cell action potential	1
regulation of cardiac muscle cell contraction	1
regulation of membrane depolarization during action potential	1
regulation of membrane depolarization during cardiac muscle cell action potential	1
positive regulation of membrane depolarization	1
regulation of sodium ion transport	1
sodium ion transmembrane transport	1
regulation of monoatomic cation transmembrane transport	1
protein localization to plasma membrane	1
regulation of protein localization to plasma membrane	1
positive regulation of protein localization to cell periphery	1
positive regulation of protein localization to membrane	1
protein localization to cell surface	1
positive regulation of protein localization	1
regulation of protein localization to cell surface	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
GTP binding	1
GDP binding	1

Protein interactions and networks

STRING

570 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RANGRF	RANBP1	P43487	864
RANGRF	SCN5A	Q14524	837
RANGRF	GPD1L	Q8N335	773
RANGRF	SCN3B	Q9NY72	771
RANGRF	KCNE3	Q9Y6H6	739
RANGRF	SCN2B	O60939	734
RANGRF	SLMAP	Q14BN4	730
RANGRF	SCN1B	Q07699	726
RANGRF	KCNE5	Q9UJ90	720
RANGRF	RAN	P17080	719
RANGRF	CACNA2D1	P54289	709
RANGRF	KCNJ8	Q15842	694
RANGRF	KCND3	Q9UK17	670
RANGRF	PKP2	Q99959	665
RANGRF	HCN4	Q9Y3Q4	623

IntAct

41 interactions, top by confidence:

A	B	Type	Score
TSEN15	TSEN54	psi-mi:“MI:0914”(association)	0.740
RANGRF	RAN	psi-mi:“MI:0914”(association)	0.640
RAN	RGPD8	psi-mi:“MI:0914”(association)	0.640
ZNF266	RANGRF	psi-mi:“MI:0915”(physical association)	0.590
SS18L2	SMARCA2	psi-mi:“MI:0914”(association)	0.570
RAN	NEMP2	psi-mi:“MI:0914”(association)	0.530
B2M	KPNA3	psi-mi:“MI:0914”(association)	0.530
IGSF6	CETN3	psi-mi:“MI:0914”(association)	0.530
WDR59	EPB41L2	psi-mi:“MI:0914”(association)	0.530
RAB30	UBB	psi-mi:“MI:0914”(association)	0.530
LRRC56	HSPA8	psi-mi:“MI:0914”(association)	0.530
RAB3A	RAB3B	psi-mi:“MI:0914”(association)	0.530
GNG2	GNB5	psi-mi:“MI:0914”(association)	0.530
RAB3A	CHM	psi-mi:“MI:0914”(association)	0.530
SRSF2	RANGRF	psi-mi:“MI:0915”(physical association)	0.500
EIF2S3	RANGRF	psi-mi:“MI:0915”(physical association)	0.400
PCTP	RANGRF	psi-mi:“MI:0915”(physical association)	0.400
RANGRF	PTPN11	psi-mi:“MI:0915”(physical association)	0.370
Ranbp2	POM121C	psi-mi:“MI:0914”(association)	0.350
MUC20	RAD51B	psi-mi:“MI:0914”(association)	0.350
SGCZ	ATP5F1B	psi-mi:“MI:0914”(association)	0.350
SAPCD1	CTNNA2	psi-mi:“MI:0914”(association)	0.350
GNG2	FAM171A2	psi-mi:“MI:0914”(association)	0.350

BioGRID (52): RANGRF (Two-hybrid), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS), RANGRF (Affinity Capture-MS)

ESM2 similar proteins: A0A5F8AH41, A0AVI4, A0JMH2, A1Y9I9, A5WVX1, B0X4N1, B4P925, D3ZX08, O55171, O88512, O95050, O97972, P0DPD7, P0DPE0, P0DPE1, P10937, P10938, P11086, P40935, P40936, Q06AU9, Q08DK0, Q14CH7, Q32PE2, Q32Q92, Q3SZG9, Q3URQ7, Q568P9, Q5E9L5, Q5JTZ9, Q5RCH4, Q5RFR7, Q6NTR1, Q6NZB1, Q7QIL2, Q7TMC8, Q80YU0, Q8HY87, Q8K304, Q8NFF5

Diamond homologs: A3KPP3, O75002, Q32PE2, Q54ML6, Q9HD47, Q9JIB0, P47123

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

153 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	83
Likely benign	55
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

601 predictions. Top by Δscore:

Variant	Effect	Δscore
17:8288675:C:G	donor_gain	0.9800
17:8288861:GTAAG:G	donor_loss	0.9800
17:8288862:TAAGG:T	donor_loss	0.9800
17:8288863:AAGGT:A	donor_loss	0.9800
17:8288864:AGG:A	donor_loss	0.9800
17:8288866:GTGAG:G	donor_loss	0.9800
17:8289079:G:T	donor_gain	0.9800
17:8289252:CTCCA:C	acceptor_loss	0.9800
17:8289253:TCCA:T	acceptor_loss	0.9800
17:8289254:CCA:C	acceptor_loss	0.9800
17:8289255:CAGG:C	acceptor_loss	0.9800
17:8289256:AGGTA:A	acceptor_loss	0.9800
17:8289398:C:G	donor_gain	0.9800
17:8289589:G:GG	donor_gain	0.9800
17:8289073:G:GG	donor_gain	0.9700
17:8288671:GGAGC:G	donor_gain	0.9600
17:8289410:AGCAG:A	donor_loss	0.9600
17:8289412:CAG:C	donor_loss	0.9600
17:8289413:AGGTG:A	donor_loss	0.9600
17:8289414:GG:G	donor_loss	0.9600
17:8289416:TGAG:T	donor_loss	0.9600
17:8289417:GAGG:G	donor_loss	0.9600
17:8288672:GAGC:G	donor_gain	0.9500
17:8288955:GC:G	acceptor_gain	0.9500
17:8288967:C:A	acceptor_gain	0.9500
17:8289050:G:GG	donor_gain	0.9500
17:8289411:GCAG:G	donor_gain	0.9500
17:8289597:G:GT	donor_gain	0.9500
17:8289811:A:G	acceptor_gain	0.9500
17:8288954:A:AG	acceptor_gain	0.9400

AlphaMissense

1211 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:8288970:T:A	V31D	0.988
17:8288816:T:C	F10L	0.983
17:8288818:C:A	F10L	0.983
17:8288818:C:G	F10L	0.983
17:8289014:A:C	S46R	0.971
17:8289016:C:A	S46R	0.971
17:8289016:C:G	S46R	0.971
17:8289922:T:C	F183L	0.971
17:8289924:T:A	F183L	0.971
17:8289924:T:G	F183L	0.971
17:8289383:G:A	G107D	0.969
17:8289018:T:C	L47P	0.966
17:8288983:A:C	Q35H	0.959
17:8288983:A:T	Q35H	0.959
17:8289564:T:C	L138P	0.959
17:8289862:T:A	W163R	0.958
17:8289862:T:C	W163R	0.958
17:8288982:A:C	Q35P	0.953
17:8289262:C:G	H67D	0.953
17:8289377:T:C	L105P	0.950
17:8288829:T:C	F14S	0.949
17:8288991:T:C	F38S	0.948
17:8289561:A:G	D137G	0.947
17:8289530:G:C	A127P	0.946
17:8289531:C:A	A127D	0.946
17:8288990:T:C	F38L	0.945
17:8288992:C:A	F38L	0.945
17:8288992:C:G	F38L	0.945
17:8288816:T:A	F10I	0.944
17:8289560:G:C	D137H	0.944

dbSNP variants (sampled 300 via entrez): RS1000293054 (17:8288471 C>A,T), RS1003532491 (17:8288728 A>T), RS1004152798 (17:8288092 C>T), RS1005420897 (17:8287043 G>A), RS1007767651 (17:8288639 G>A,C), RS1008717766 (17:8289556 G>A), RS1008791126 (17:8289231 C>T), RS1009475957 (17:8288578 C>T), RS1010842675 (17:8289193 A>G), RS1011178032 (17:8288058 C>T), RS1011923566 (17:8290465 C>T), RS1011955967 (17:8286986 A>C), RS1014363160 (17:8289715 G>A,C), RS1014428533 (17:8289186 G>A), RS1017300154 (17:8289232 T>A)

Disease associations

OMIM: gene MIM:607954 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Brugada syndrome	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
Brugada syndrome	Refuted	AD

Mondo (2): cardiac rhythm disease (MONDO:0007263), Brugada syndrome (MONDO:0015263)

Orphanet (0):

HPO phenotypes

12 total (12 of 12 shown, HPO-id order):

HPO	Term
HP:0001279	Syncope
HP:0001649	Tachycardia
HP:0001663	Ventricular fibrillation
HP:0001695	Cardiac arrest
HP:0004308	Ventricular arrhythmia
HP:0004751	Paroxysmal ventricular tachycardia
HP:0004755	Supraventricular tachycardia
HP:0011704	Sick sinus syndrome
HP:0011705	First degree atrioventricular block
HP:0011712	Complete right bundle branch block
HP:0011715	Trifascicular block
HP:0012251	ST segment elevation

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D053840	Brugada Syndrome	C14.280.067.322; C14.280.123.250; C16.320.100

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
cobaltous chloride	decreases expression	2
arsenite	affects binding, increases reaction	1
CGP 52608	affects binding, increases reaction	1
NSC 689534	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Cadmium	increases abundance, increases expression	1
Methyl Methanesulfonate	decreases expression	1
Phthalic Acids	increases methylation	1
Theophylline	increases expression	1
Tretinoin	decreases expression	1
Cyclosporine	increases expression	1
Cadmium Chloride	increases abundance, increases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
Acrylamide	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D0PZ	WYUi002-A	Induced pluripotent stem cell	Female

Clinical trials (associated diseases)

307 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00702117	PHASE4	COMPLETED	Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias
NCT00146822	PHASE4	COMPLETED	REFLEx Study (ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance
NCT00187239	PHASE4	COMPLETED	Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search Study
NCT00247533	PHASE4	UNKNOWN	Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia
NCT00282620	PHASE4	UNKNOWN	Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient’s Quality of Life.
NCT00290056	PHASE4	UNKNOWN	Effect of Supplemental Intake of Omega-3 Polyunsaturated Fatty Acids on the Rate and Complexity of Spontaneously Occurring Ventricular and Supraventricular Arrhythmias in Patients With Implantable Cardioverter Defibrillator (ICD) - A Randomized Clinical Trial
NCT00313443	PHASE4	COMPLETED	Concentrations of Amiodarone in Fat Tissue During Chronic Treatment
NCT00457340	PHASE4	COMPLETED	Atorvastatin For The Reduction Of Ventricular Arrhythmias
NCT00507390	PHASE4	WITHDRAWN	Omega 3 Polyunsaturated Fatty Acid Supplements (PUFAs) and Microvolt T Wave Alternans (TWA) in Patients With Ventricular Arrhythmia
NCT00575523	PHASE4	COMPLETED	Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy
NCT00579098	PHASE4	COMPLETED	The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation
NCT01613092	PHASE4	COMPLETED	Prevention of Arrhythmia Device Infection Trial (PADIT)
NCT01628666	PHASE4	COMPLETED	Prevention of Arrhythmia Device Infection Trial (PADIT)
NCT01717469	PHASE4	UNKNOWN	Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias
NCT01819064	PHASE4	COMPLETED	Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants
NCT01834872	PHASE4	UNKNOWN	Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation
NCT01841242	PHASE4	COMPLETED	Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation
NCT01991223	PHASE4	UNKNOWN	Dexmedetomidine for Catheter-related Bladder Discomfort
NCT02045173	PHASE4	COMPLETED	Automate Detection of Sleep Apnea by ApneascanTM
NCT02203630	PHASE4	TERMINATED	Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients
NCT02565069	PHASE4	COMPLETED	Identification for the Treatment of Complex Arrhythmias
NCT03273634	PHASE4	COMPLETED	The Effect of Proton Pump Inhibition on Palpitations
NCT03289429	PHASE4	UNKNOWN	Antiarrhythmic and Cardioprotective Effects of Atorvastatin Versus Magnesium Sulfate in Cardiac Valve Replacement Surgery
NCT03895411	PHASE4	UNKNOWN	Efficacy and Safety of Sotalol in Children With Arrhythmia
NCT05486377	PHASE4	COMPLETED	Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia
NCT06574555	PHASE4	COMPLETED	Norepinephrine ED90 Bolus After Spinal Anesthesia in Cesarean Section
NCT00701077	PHASE3	TERMINATED	DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome
NCT00927732	PHASE3	TERMINATED	Hydroquinidine Versus Placebo in Patients With Brugada Syndrome
NCT00000464	PHASE3	COMPLETED	Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
NCT00000476	PHASE3	COMPLETED	Digitalis Investigation Group (DIG)
NCT00000480	PHASE3	COMPLETED	Multicenter Unsustained Tachycardia Trial (MUSTT)
NCT00000492	PHASE3	COMPLETED	Beta-Blocker Heart Attack Trial (BHAT)
NCT00000502	PHASE3	COMPLETED	Evaluation of SC-V Versus Conventional CPR
NCT00000517	PHASE3	COMPLETED	Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)
NCT00000518	PHASE3	COMPLETED	Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)
NCT00000531	PHASE3	COMPLETED	Antiarrhythmics Versus Implantable Defibrillators (AVID)
NCT00000540	PHASE3	COMPLETED	Coronary Artery Bypass Graft (CABG) Patch Trial
NCT00000556	PHASE3	COMPLETED	Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
NCT00000561	PHASE3	COMPLETED	Mode Selection Trial in Sinus Node Dysfunction (MOST)
NCT00000609	PHASE3	COMPLETED	Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)